Press Release

Press Release

  • (2023-03-15) Aimed-GeneQuantum reveals 'FGFR3-ADC' preclinical data at "World ADC"
  • - The preclinical study result of Aimed-GeneQuantum co-developing 'FGFR3-ADC' "AMB302/GQ1011" will be presented at the "World ADC".

    - They have confirmed AMB302/GQ1011's anti-tumor effect in both bladder cancer and GBM cancer models, and plan to submit IND and start phase 1 clinical trial in 1H 2024.

    Link to full news

Contact Us >>